Association between aspirin dose and outcomes in patients with acute Kawasaki disease : a nationwide retrospective cohort study in Japan
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature..
This study aimed to identify the appropriate dose of aspirin to be prescribed to patients with acute Kawasaki disease (KD). Using a Japanese national inpatient database, we identified patients with KD treated with intravenous immunoglobulin between 2010 and 2021.The outcomes included the occurrence of coronary artery abnormalities and intravenous immunoglobulin resistance, length of hospital stay, and medical costs. Restricted cubic spline functions were performed to examine the association between aspirin dose and the outcomes. Data of 82,109 patients were extracted from the database. Non-linear associations were observed between aspirin dose and the outcomes. In comparison with an aspirin dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for coronary artery abnormalities was 1.40 (1.13-1.75) at 5 mg/kg/day. An aspirin dose of ≥ 30 mg/kg/day did not significantly change the odds ratio for coronary artery abnormalities. Intravenous immunoglobulin resistance was significantly lower at a dose of 60 mg/kg/day or higher.
CONCLUSION: The results showed no significant association between aspirin escalation over standard-dose and coronary artery abnormalities in patients with acute KD. High-dose aspirin showed the potential to reduce hospital stay and medical costs without increasing complications.
WHAT IS KNOWN: • Aspirin is used as a standard treatment together with intravenous immunoglobulin for acute Kawasaki disease (KD). However, few studies have shown the most effective dosage of aspirin to prevent coronary artery abnormalities (CAAs).
WHAT IS NEW: • There was no significant association between aspirin dose escalation and CAAs in patients with acute KD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:183 |
|---|---|
| Enthalten in: |
European journal of pediatrics - 183(2024), 1 vom: 15. Jan., Seite 415-424 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Suzuki, Takanori [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Aspirin |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 18.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00431-023-05302-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36409057X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36409057X | ||
| 003 | DE-627 | ||
| 005 | 20240318233800.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00431-023-05302-8 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1334.xml |
| 035 | |a (DE-627)NLM36409057X | ||
| 035 | |a (NLM)37917176 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Suzuki, Takanori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Association between aspirin dose and outcomes in patients with acute Kawasaki disease |b a nationwide retrospective cohort study in Japan |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 18.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature. | ||
| 520 | |a This study aimed to identify the appropriate dose of aspirin to be prescribed to patients with acute Kawasaki disease (KD). Using a Japanese national inpatient database, we identified patients with KD treated with intravenous immunoglobulin between 2010 and 2021.The outcomes included the occurrence of coronary artery abnormalities and intravenous immunoglobulin resistance, length of hospital stay, and medical costs. Restricted cubic spline functions were performed to examine the association between aspirin dose and the outcomes. Data of 82,109 patients were extracted from the database. Non-linear associations were observed between aspirin dose and the outcomes. In comparison with an aspirin dose of 30 mg/kg/day, the odds ratio (95% confidence interval) for coronary artery abnormalities was 1.40 (1.13-1.75) at 5 mg/kg/day. An aspirin dose of ≥ 30 mg/kg/day did not significantly change the odds ratio for coronary artery abnormalities. Intravenous immunoglobulin resistance was significantly lower at a dose of 60 mg/kg/day or higher | ||
| 520 | |a CONCLUSION: The results showed no significant association between aspirin escalation over standard-dose and coronary artery abnormalities in patients with acute KD. High-dose aspirin showed the potential to reduce hospital stay and medical costs without increasing complications | ||
| 520 | |a WHAT IS KNOWN: • Aspirin is used as a standard treatment together with intravenous immunoglobulin for acute Kawasaki disease (KD). However, few studies have shown the most effective dosage of aspirin to prevent coronary artery abnormalities (CAAs) | ||
| 520 | |a WHAT IS NEW: • There was no significant association between aspirin dose escalation and CAAs in patients with acute KD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Aspirin | |
| 650 | 4 | |a Coronary artery abnormalities | |
| 650 | 4 | |a Kawasaki disease | |
| 650 | 4 | |a Restricted cubic spline | |
| 650 | 7 | |a Immunoglobulins, Intravenous |2 NLM | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 700 | 1 | |a Michihata, Nobuaki |e verfasserin |4 aut | |
| 700 | 1 | |a Hashimoto, Yohei |e verfasserin |4 aut | |
| 700 | 1 | |a Yoshikawa, Tetsushi |e verfasserin |4 aut | |
| 700 | 1 | |a Saito, Kazuyoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Matsui, Hiroki |e verfasserin |4 aut | |
| 700 | 1 | |a Fushimi, Kiyohide |e verfasserin |4 aut | |
| 700 | 1 | |a Yasunaga, Hideo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of pediatrics |d 1978 |g 183(2024), 1 vom: 15. Jan., Seite 415-424 |w (DE-627)NLM000029718 |x 1432-1076 |7 nnns |
| 773 | 1 | 8 | |g volume:183 |g year:2024 |g number:1 |g day:15 |g month:01 |g pages:415-424 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00431-023-05302-8 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 183 |j 2024 |e 1 |b 15 |c 01 |h 415-424 | ||